查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2030 年融合蛋白市场预测：按类型、应用和地区分類的全球分析
市场调查报告书
商品编码
1383409

2030 年融合蛋白市场预测：按类型、应用和地区分類的全球分析

Fusion Proteins Market Forecasts to 2030 - Global Analysis By Type (Immunoglobulin Fusion Protein, Parathyroid Hormone Fusion Protein, Cytokines Recombinant Fusion Protein and Other Types), By Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球融合蛋白市场规模将达到 298 亿美元，预计到 2030 年将达到 454 亿美元，预测期内年复合成长率为 6.2%。

融合蛋白是透过连接两个或多个编码单独蛋白质的基因而製成的人造蛋白质。这些混合蛋白用于多种应用，包括生物技术和医学。在生物技术中，融合蛋白用于生产大量用于研究或治疗目的的特定蛋白质。它们也可以用作蛋白质精製的分子标籤或作为研究蛋白质相互作用的工具。

根据 Globocan 2020，新报告的癌症病例数为 19,292,789 例，预计到 2040 年将增加到 28,887,940 例。

慢性病增加

随着内容和分发管道变得越来越数位化，越来越需要保护宝贵的智慧财产权免受骇客攻击、资料外洩和诈欺的分发等网路威胁。 DRM 解决方案提供强大的加密、存取控制和监控功能，使网路犯罪分子难以破坏或窃取敏感内容。因此，娱乐、出版和软体开发等行业越来越多地采用 DRM 技术来保护自家公司资产，确保内容安全并降低因网路攻击和盗版而造成收益损失的风险。

开发成本高

将融合蛋白疗法推向市场所需的研究、开发和临床试验需要大量资金。这些成本包括临床前测试、广泛的临床试验、法规遵循、製造基础设施等。高开发成本对于中小型生技公司来说尤其困难，并且会限制创新和竞争力。为了克服这些限制，合作研究、官民合作关係和资助计画对于支持融合蛋白的研究和开发至关重要。此外，具有成本效益的开发策略和高效的临床试验设计可以帮助减轻这种经济负担，并最终加速这一重要治疗领域的成长。

改进药物传输技术

奈米颗粒、脂质体和缀合物等药物递送系统的改进为最佳化基于融合蛋白的治疗药物的给药和疗效提供了潜力。这些技术可以提高融合蛋白的稳定性、生物利用度以及向特定细胞和组织的标靶递送，最大限度地减少脱靶效应，并提高整体治疗效果。随着药物传递创新的不断进行，融合蛋白疗法对于多种疾病状态将变得更具吸引力，因为它们不仅会扩大其适用性，而且会提高患者的依从性和舒适度，推动市场成长，并促进技术创新。

安全问题和潜在的副作用

与其他生物製药一样，融合蛋白也存在副作用和意外后果的风险。确保此类治疗方法的安全性至关重要，任何问题都可能导致法规挫折、公众怀疑和市场不确定性。在临床试验期间对候选融合蛋白进行严格评估和监测对于降低这些风险至关重要。解决安全问题需要持续监测、药物警戒和製定风险管理策略。最终，维持良好的效益风险比对于融合蛋白疗法的市场接受度和长期成功至关重要。

COVID-19 的影响：

COVID-19 大流行对融合蛋白市场产生了各种影响。虽然临床试验和供应链暂时中断，但生物製药研发的重要性却凸显出来。融合蛋白是治疗性介入的多功能候选者，因此人们对其在 COVID-19 治疗和疫苗开发方面的潜力越来越感兴趣。此次疫情加速了生物技术研究，间接惠及融合蛋白部门。然而，对 COVID-19 相关治疗的不确定性和关注暂时转移了其他医疗条件的资源和注意力，影响了融合蛋白市场研发的整体步伐。

免疫球蛋白（Ig）融合部分预计在预测期内是最大的

免疫球蛋白（Ig）融合部分预计将出现良好的成长。这些工程蛋白质将抗体的抗原特异性辨识与另一种感兴趣的蛋白质或胜肽结合。 Ig融合蛋白广泛应用于生物製药，作为癌症、自体免疫疾病、感染疾病等多种疾病的标靶治疗。此外，它也是诊断的重要工具，有助于准确检测特定的生物标记。 Ig融合蛋白处于个人化医疗的最前沿，提供客製化的治疗方案和创新的研究途径，为融合蛋白市场的成长和开拓做出了重大贡献。

生物技术产业预计在预测期内年复合成长率最高

预计生物技术产业在预测期内将以最快的年复合成长率成长。基因工程、重组 DNA 技术和蛋白质表现系统的进步使得能够创造具有改善的治疗特性的复杂融合蛋白。生物技术工具和技术有助于精确设计和修饰融合蛋白，以针对特定疾病或途径。生技公司在这一领域不断创新，并推动融合蛋白疗法的成长。此外，生物技术的进步促进了高效製造、品管和新型药物传输技术的开发，使融合蛋白成为现代生物製药创新的基石。

占比最大的地区：

在预测期内，由于北美市场先进的医疗基础设施、强大的生物技术部门以及重要的研发活动，预计将继续占据大部分市场占有率。尤其是美国和加拿大，处于基于融合蛋白的治疗方法的创新和临床试验的前沿。这些国家拥有完善的法律规范和支持政策，鼓励生物製药的开发和商业化。此外，慢性病盛行率的不断上升、对个人化医疗的日益重视以及对医疗保健研究的大量投资，都有助于该地区在融合蛋白市场中占据主导地位。

复合年复合成长率最高的地区：

亚太地区在香料兰姆酒市场中发挥重要作用，预计在预测期内复合年复合成长率最高。该地区不断扩大的製药和生物技术行业以及庞大的患者群体带来了巨大的商机。亚太地区的研发投资不断增加，中国和印度等国家成为生物製药生产中心。此外，慢性病的盛行率正在上升，推动了对创新治疗方法（包括融合蛋白）的需求。亚太地区的市场成长潜力、临床试验和製造能力使其成为寻求进入该地区不断扩大的医疗保健市场的全球生物製药公司的重点关注点。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 应用分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球融合蛋白市场：依类型

  • 免疫球蛋白 (Ig) 融合蛋白
  • 副甲状腺素(PTH) 融合蛋白
  • 细胞激素重组融合蛋白
  • 其他类型

第6章全球融合蛋白市场：依应用

  • 嵌合蛋白药物
  • 生物技术
  • 诊断
  • 药物输送
  • 其他用途

第7章全球融合蛋白市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第8章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第9章公司简介

  • Abnova
  • Roche
  • Chimerigen
  • Peprotech
  • Amgen Science
  • Astellas Pharma
  • Bristol-Myers Squibb
  • ProSpec
  • Viventia
  • Genzyme
  • Ligand Pharmaceuticals
  • Novus
  • Regeneron
  • Origene
  • Absolute Antibody
Product Code: SMRC24258

According to Stratistics MRC, the Global Fusion Proteins Market is accounted for $29.8 billion in 2023 and is expected to reach $45.4 billion by 2030 growing at a CAGR of 6.2% during the forecast period. Fusion proteins are artificial proteins created by joining two or more genes that code for separate proteins. These hybrid proteins serve various purposes, such as in biotechnology and medicine. In biotechnology, fusion proteins are used to produce specific proteins in large quantities for research or therapeutic purposes. They can also be utilized as molecular tags for protein purification or as tools for studying protein interactions.

According to Globocan 2020, there were 19,292,789 new cases of cancer reported, and this number is expected to increase to 28,887,940 by 2040.

Market Dynamics:

Driver:

Increasing prevalence of chronic diseases

With the growing digitization of content and distribution channels, there is a greater need to protect valuable intellectual property from cyber threats such as hacking, data breaches, and unauthorized distribution. DRM solutions offer robust encryption, access controls, and monitoring capabilities, making it harder for cybercriminals to compromise and steal sensitive content. As a result, industries like entertainment, publishing, and software development are increasingly adopting DRM technologies to safeguard their assets, ensuring content security and reducing the risk of revenue loss due to cyber attacks and piracy.

Restraint:

High development Costs

The research, development, and clinical testing required bringing fusion protein therapies to market demand substantial financial investment. These costs encompass preclinical studies, extensive clinical trials, regulatory compliance, and manufacturing infrastructure. High development expenses can be especially challenging for smaller biotech companies, potentially limiting their ability to innovate and compete. To overcome this restraint, collaboration, public-private partnerships, and funding initiatives are essential to support the research and development of fusion proteins. Additionally, cost-effective development strategies and efficient clinical trial design can help alleviate this financial burden, ultimately fostering the growth of this vital therapeutic sector.

Opportunity:

Improving drug delivery technologies

Enhanced drug delivery systems, such as nanoparticles, liposomes, and conjugates, offer the potential to optimize the administration and effectiveness of fusion protein-based therapies. These technologies can improve the stability, bioavailability, and targeted delivery of fusion proteins to specific cells or tissues, minimizing off-target effects and enhancing overall treatment outcomes. As drug delivery innovations continue to evolve, they not only expand the applicability of fusion proteins but also enhance patient compliance and comfort, making fusion protein therapies more attractive for a wide range of medical conditions and thus driving market growth and innovation.

Threat:

Safety concerns and potential side effects

Fusion proteins, like all biopharmaceuticals, can carry risks of adverse reactions or unintended consequences. Ensuring the safety profile of these therapies is crucial, as any issues can lead to regulatory setbacks, public skepticism, and market uncertainty. The rigorous evaluation and monitoring of fusion protein candidates during clinical trials are essential to mitigate these risks. Addressing safety concerns demands continuous research, pharmacovigilance, and the development of risk management strategies. Ultimately, maintaining a favorable benefit-to-risk ratio is imperative for the market acceptance and long-term success of fusion protein therapies.

COVID-19 Impact:

The COVID-19 pandemic has had mixed effects on the Fusion Proteins market. While it momentarily disrupted some clinical trials and supply chains, it also underscored the importance of biopharmaceutical research and development. Fusion proteins, being versatile candidates for therapeutic interventions, have seen increased interest in potential COVID-19 treatments and vaccine development. The pandemic has accelerated research in biotechnology, thereby indirectly benefiting the fusion proteins sector. However, the uncertainties and focus on COVID-19-related therapies temporarily diverted resources and attention from other medical conditions, impacting the overall pace of research and development in the Fusion Proteins market.

The immunoglobulin (Ig) fusion segment is expected to be the largest during the forecast period

The immunoglobulin (Ig) fusion segment is expected to have a lucrative growth. These engineered proteins combine an antibody's antigen-specific recognition with another protein or peptide of interest. They find extensive use in biopharmaceuticals, offering targeted therapies for a variety of diseases, including cancers, autoimmune disorders, and infectious diseases. Additionally, they serve as indispensable tools in diagnostics, facilitating the precise detection of specific biomarkers. Ig Fusion Proteins are at the forefront of personalized medicine, providing tailored treatment options and innovative research avenues, contributing significantly to the growth and development of the Fusion Proteins market.

The biological technology segment is expected to have the highest CAGR during the forecast period

The biological technology segment is anticipated to witness the fastest CAGR growth during the forecast period. Advances in genetic engineering, recombinant DNA technology, and protein expression systems have enabled the creation of complex fusion proteins with enhanced therapeutic properties. Biotechnology tools and techniques facilitate the precise design and modification of fusion proteins to target specific diseases and pathways. Biotech companies are continuously innovating in this field, driving the growth of fusion protein therapies. Moreover, biotechnological advancements contribute to efficient manufacturing, quality control, and the development of novel drug delivery technologies, making fusion proteins a cornerstone of modern biopharmaceutical innovation.

Region with largest share:

During the forecast period, it is expected that the North American market will continue to hold a majority of the market share due to its advanced healthcare infrastructure, robust biotechnology sector, and significant research and development activities. The United States and Canada, in particular, have been at the forefront of innovation and clinical trials for fusion protein-based therapies. These nations have well-established regulatory frameworks and supportive policies that encourage the development and commercialization of biopharmaceuticals. Additionally, the increasing prevalence of chronic diseases, a growing emphasis on personalized medicine, and substantial investment in healthcare research contribute to the region's dominance in the Fusion Proteins market.

Region with highest CAGR:

The Asia Pacific region plays a significant role in the spice rum market and is projected to have the highest CAGR over the forecast period. The region's expanding pharmaceutical and biotechnology industry, coupled with a large patient population, presents significant opportunities. Asia Pacific is witnessing increased investment in research and development, with countries like China and India becoming hubs for biopharmaceutical production. Furthermore, the prevalence of chronic diseases is on the rise, driving the demand for innovative therapies, including fusion proteins. Asia Pacific's potential for market growth, clinical trials, and manufacturing capabilities make it a key focus for global biopharmaceutical companies aiming to tap into the region's expanding healthcare market.

Key players in the market

Some of the key players in Fusion Proteins market include: Abnova, Roche, Chimerigen, Peprotech, Amgen Science, Astellas Pharma, Bristol-Myers Squibb, ProSpec, Viventia, Genzyme, Ligand Pharmaceuticals, Novus, Regeneron, Origene and Absolute Antibody.

Key Developments:

In August 2022, Amgen Inc. and Teneobio Inc. announced a deal in which Amgen would acquire Teneobio, which is a privately owned clinical-stage biotechnology firm focusing on a novel class of biologics known as Human Heavy-Chain Antibodies. Amgen's capabilities to develop advanced medicine in treating patients with severe diseases and commercialize best-in-class products will be strengthened by the acquisition of Teneobio.

In July 2022, Formation Biologics Inc., which is a protein engineering business specializing in biotherapeutics for cancer and fibrotic disorders was acquired by Bristol-Myers Squibb Company. Bristol-Myers Squibb acquired Forbius' TGF-beta program, including the lead experimental option, AVID200, as part of the acquisition. Primarily, Bristol-Myers Squibb intends to focus on AVID200 R&D in cancer detection, with the possibility of broadening its application to other therapeutic areas such as fibrosis.

Types Covered:

  • Immunoglobulin (Ig) Fusion Protein
  • Parathyroid Hormone (PTH) Fusion Protein
  • Cytokines Recombinant Fusion Protein
  • Other Types

Applications Covered:

  • Chimeric Protein Drugs
  • Biological Technology
  • Diagnostics
  • Drug Delivery
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Fusion Proteins Market, By Type

  • 5.1 Introduction
  • 5.2 Immunoglobulin (Ig) Fusion Protein
  • 5.3 Parathyroid Hormone (PTH) Fusion Protein
  • 5.4 Cytokines Recombinant Fusion Protein
  • 5.5 Other Types

6 Global Fusion Proteins Market, By Application

  • 6.1 Introduction
  • 6.2 Chimeric Protein Drugs
  • 6.3 Biological Technology
  • 6.4 Diagnostics
  • 6.5 Drug Delivery
  • 6.6 Other Applications

7 Global Fusion Proteins Market, By Geography

  • 7.1 Introduction
  • 7.2 North America
    • 7.2.1 US
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 Italy
    • 7.3.4 France
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 Japan
    • 7.4.2 China
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 New Zealand
    • 7.4.6 South Korea
    • 7.4.7 Rest of Asia Pacific
  • 7.5 South America
    • 7.5.1 Argentina
    • 7.5.2 Brazil
    • 7.5.3 Chile
    • 7.5.4 Rest of South America
  • 7.6 Middle East & Africa
    • 7.6.1 Saudi Arabia
    • 7.6.2 UAE
    • 7.6.3 Qatar
    • 7.6.4 South Africa
    • 7.6.5 Rest of Middle East & Africa

8 Key Developments

  • 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 8.2 Acquisitions & Mergers
  • 8.3 New Product Launch
  • 8.4 Expansions
  • 8.5 Other Key Strategies

9 Company Profiling

  • 9.1 Abnova
  • 9.2 Roche
  • 9.3 Chimerigen
  • 9.4 Peprotech
  • 9.5 Amgen Science
  • 9.6 Astellas Pharma
  • 9.7 Bristol-Myers Squibb
  • 9.8 ProSpec
  • 9.9 Viventia
  • 9.10 Genzyme
  • 9.11 Ligand Pharmaceuticals
  • 9.12 Novus
  • 9.13 Regeneron
  • 9.14 Origene
  • 9.15 Absolute Antibody

List of Tables

  • Table 1 Global Fusion Proteins Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Fusion Proteins Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Fusion Proteins Market Outlook, By Immunoglobulin (Ig) Fusion Protein (2021-2030) ($MN)
  • Table 4 Global Fusion Proteins Market Outlook, By Parathyroid Hormone (PTH) Fusion Protein (2021-2030) ($MN)
  • Table 5 Global Fusion Proteins Market Outlook, By Cytokines Recombinant Fusion Protein (2021-2030) ($MN)
  • Table 6 Global Fusion Proteins Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 7 Global Fusion Proteins Market Outlook, By Application (2021-2030) ($MN)
  • Table 8 Global Fusion Proteins Market Outlook, By Chimeric Protein Drugs (2021-2030) ($MN)
  • Table 9 Global Fusion Proteins Market Outlook, By Biological Technology (2021-2030) ($MN)
  • Table 10 Global Fusion Proteins Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 11 Global Fusion Proteins Market Outlook, By Drug Delivery (2021-2030) ($MN)
  • Table 12 Global Fusion Proteins Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 13 North America Fusion Proteins Market Outlook, By Country (2021-2030) ($MN)
  • Table 14 North America Fusion Proteins Market Outlook, By Type (2021-2030) ($MN)
  • Table 15 North America Fusion Proteins Market Outlook, By Immunoglobulin (Ig) Fusion Protein (2021-2030) ($MN)
  • Table 16 North America Fusion Proteins Market Outlook, By Parathyroid Hormone (PTH) Fusion Protein (2021-2030) ($MN)
  • Table 17 North America Fusion Proteins Market Outlook, By Cytokines Recombinant Fusion Protein (2021-2030) ($MN)
  • Table 18 North America Fusion Proteins Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 19 North America Fusion Proteins Market Outlook, By Application (2021-2030) ($MN)
  • Table 20 North America Fusion Proteins Market Outlook, By Chimeric Protein Drugs (2021-2030) ($MN)
  • Table 21 North America Fusion Proteins Market Outlook, By Biological Technology (2021-2030) ($MN)
  • Table 22 North America Fusion Proteins Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 23 North America Fusion Proteins Market Outlook, By Drug Delivery (2021-2030) ($MN)
  • Table 24 North America Fusion Proteins Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 25 Europe Fusion Proteins Market Outlook, By Country (2021-2030) ($MN)
  • Table 26 Europe Fusion Proteins Market Outlook, By Type (2021-2030) ($MN)
  • Table 27 Europe Fusion Proteins Market Outlook, By Immunoglobulin (Ig) Fusion Protein (2021-2030) ($MN)
  • Table 28 Europe Fusion Proteins Market Outlook, By Parathyroid Hormone (PTH) Fusion Protein (2021-2030) ($MN)
  • Table 29 Europe Fusion Proteins Market Outlook, By Cytokines Recombinant Fusion Protein (2021-2030) ($MN)
  • Table 30 Europe Fusion Proteins Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 31 Europe Fusion Proteins Market Outlook, By Application (2021-2030) ($MN)
  • Table 32 Europe Fusion Proteins Market Outlook, By Chimeric Protein Drugs (2021-2030) ($MN)
  • Table 33 Europe Fusion Proteins Market Outlook, By Biological Technology (2021-2030) ($MN)
  • Table 34 Europe Fusion Proteins Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 35 Europe Fusion Proteins Market Outlook, By Drug Delivery (2021-2030) ($MN)
  • Table 36 Europe Fusion Proteins Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 37 Asia Pacific Fusion Proteins Market Outlook, By Country (2021-2030) ($MN)
  • Table 38 Asia Pacific Fusion Proteins Market Outlook, By Type (2021-2030) ($MN)
  • Table 39 Asia Pacific Fusion Proteins Market Outlook, By Immunoglobulin (Ig) Fusion Protein (2021-2030) ($MN)
  • Table 40 Asia Pacific Fusion Proteins Market Outlook, By Parathyroid Hormone (PTH) Fusion Protein (2021-2030) ($MN)
  • Table 41 Asia Pacific Fusion Proteins Market Outlook, By Cytokines Recombinant Fusion Protein (2021-2030) ($MN)
  • Table 42 Asia Pacific Fusion Proteins Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 43 Asia Pacific Fusion Proteins Market Outlook, By Application (2021-2030) ($MN)
  • Table 44 Asia Pacific Fusion Proteins Market Outlook, By Chimeric Protein Drugs (2021-2030) ($MN)
  • Table 45 Asia Pacific Fusion Proteins Market Outlook, By Biological Technology (2021-2030) ($MN)
  • Table 46 Asia Pacific Fusion Proteins Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 47 Asia Pacific Fusion Proteins Market Outlook, By Drug Delivery (2021-2030) ($MN)
  • Table 48 Asia Pacific Fusion Proteins Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 49 South America Fusion Proteins Market Outlook, By Country (2021-2030) ($MN)
  • Table 50 South America Fusion Proteins Market Outlook, By Type (2021-2030) ($MN)
  • Table 51 South America Fusion Proteins Market Outlook, By Immunoglobulin (Ig) Fusion Protein (2021-2030) ($MN)
  • Table 52 South America Fusion Proteins Market Outlook, By Parathyroid Hormone (PTH) Fusion Protein (2021-2030) ($MN)
  • Table 53 South America Fusion Proteins Market Outlook, By Cytokines Recombinant Fusion Protein (2021-2030) ($MN)
  • Table 54 South America Fusion Proteins Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 55 South America Fusion Proteins Market Outlook, By Application (2021-2030) ($MN)
  • Table 56 South America Fusion Proteins Market Outlook, By Chimeric Protein Drugs (2021-2030) ($MN)
  • Table 57 South America Fusion Proteins Market Outlook, By Biological Technology (2021-2030) ($MN)
  • Table 58 South America Fusion Proteins Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 59 South America Fusion Proteins Market Outlook, By Drug Delivery (2021-2030) ($MN)
  • Table 60 South America Fusion Proteins Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 61 Middle East & Africa Fusion Proteins Market Outlook, By Country (2021-2030) ($MN)
  • Table 62 Middle East & Africa Fusion Proteins Market Outlook, By Type (2021-2030) ($MN)
  • Table 63 Middle East & Africa Fusion Proteins Market Outlook, By Immunoglobulin (Ig) Fusion Protein (2021-2030) ($MN)
  • Table 64 Middle East & Africa Fusion Proteins Market Outlook, By Parathyroid Hormone (PTH) Fusion Protein (2021-2030) ($MN)
  • Table 65 Middle East & Africa Fusion Proteins Market Outlook, By Cytokines Recombinant Fusion Protein (2021-2030) ($MN)
  • Table 66 Middle East & Africa Fusion Proteins Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 67 Middle East & Africa Fusion Proteins Market Outlook, By Application (2021-2030) ($MN)
  • Table 68 Middle East & Africa Fusion Proteins Market Outlook, By Chimeric Protein Drugs (2021-2030) ($MN)
  • Table 69 Middle East & Africa Fusion Proteins Market Outlook, By Biological Technology (2021-2030) ($MN)
  • Table 70 Middle East & Africa Fusion Proteins Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 71 Middle East & Africa Fusion Proteins Market Outlook, By Drug Delivery (2021-2030) ($MN)
  • Table 72 Middle East & Africa Fusion Proteins Market Outlook, By Other Applications (2021-2030) ($MN)